Recardio GmbH is developing a DPP-4 inhibitor in acute myocardial infarction to promote cardiac tissue regeneration and avoid subsequent heart failure. The compound could offer a less invasive alternative to stem cell transplantation procedures.

Current therapies fail to adequately control tissue damage caused by the ischemia and reperfusion following a heart attack. As a result, more than 20% of patients progress to heart failure within six years of a heart attack.